Communiqués Dermapharm Holding SE

Actions

DMP

DE000A2GS5D8

Produits pharmaceutiques

Marché Fermé - Xetra 17:35:21 09/09/2026			Varia. 5j.	Varia. 1 janv.
38,80 ^EUR	-0,39%		-0,51%	-1,40%

03/09	Dermapharm Holding SE : Jefferies maintient son opinion neutre	ZD
27/08	Dermapharm Holding SE : Berenberg optimiste sur le dossier	ZD

Communiqués

25/08	Dermapharm confirms profitable growth in H1 2026 and increases adjusted EBITDA	EQ
11/08	Dermapharm Holding SE reports profitable growth in H1 2026 and confirms guidance	EQ
26/06	Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.88 per share	EQ
15/05	DERMAPHARM : Q1 2026 TRANSCRIPT TELEPHONE CONFERENCE	PU
15/05	Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy	EQ
13/05	Dermapharm Holding SE performs in line with projections in Q1 2026 and confirms guidance	EQ
13/05	DERMAPHARM : Q1 2026 INTERIM STATEMENT	PU
13/05	DERMAPHARM : Q1 2026 WEBCAST	PU
04/05	Dermapharm Holding SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	EQ
09/04	DERMAPHARM : FY 2025 TRANSCRIPT TELEPHONE CONFERENCE	PU
09/04	DERMAPHARM : FY 2025 TRANSKRIPT TELEFONKONFERENZ	PU
31/03	DERMAPHARM : FY 2025 ANNUAL REPORT	PU
31/03	Dermapharm : Webcast fy 2025	PU
31/03	Dermapharm Holding SE reports dip in revenue, rise in adjusted consolidated EBITDA and margin	EQ
31/03	Dermapharm : reports dip in revenue, rise in adjusted consolidated EBITDA and margin	PU
26/03	Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer	EQ
10/03	Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares	EQ
10/03	Dermapharm Holding SE records decline in consolidated revenue, adjusted consolidated EBITDA improves	EQ
07/01	Dermapharm Holding SE: Christof Dreibholz, buy	EQ
10/12	Dermapharm Holding SE: Themis Beteiligungs-Aktiengesellschaft, buy	EQ
17/11	DERMAPHARM : Q3 2025 TRANSCRIPT TELEPHONE CONFERENCE	PU
17/11	DERMAPHARM : Q3 2025 TRANSKRIPT TELEFONKONFERENZ	PU
13/11	DERMAPHARM : Q3 2025 INTERIM STATEMENT	PU
13/11	Dermapharm : WEBCAST Q3 2025	PU
13/11	Stable earnings despite portfolio adjustment - 2025 guidance confirmed, strong growth in branded pharmaceuticals	EQ